VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | Achieving successful TFR in CML & recommendations for monitoring after treatment discontinuation

Fadi Haddad, MD, University of Texas MD Anderson Cancer Center, Houston, TX, explains the rationale for treatment discontinuation in chronic myeloid leukemia (CML), highlighting the results of a recent study investigating the factors associated with successful treatment-free remission (TFR). Overall, the study demonstrated that patients who remained in deep molecular response for five years or more had a higher chance of achieving a successful TFR in the long term. In addition, whilst current guidelines indicate that patients should be monitored every four weeks for the first six months after treatment discontinuation, the study showed that monitoring patients every six to eight weeks did not have an impact on TFR success. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter